Drug Repurposing Strategy
Accelerating Development Through Alternative Regulatory Pathways
Leveraging existing clinical data and proven compounds to accelerate the development of high-impact antiviral therapies.
A Strategic Approach to Drug Repurposing
Drug repurposing is a core component of Island Pharmaceuticals’ strategy, focused on identifying new antiviral applications for compounds that have already been approved, discontinued, or previously studied in humans. By targeting known viral mechanisms and building on established research, Island is able to reduce development risk, lower costs and significantly accelerate timelines compared to traditional drug discovery.
This approach leverages prior investment in manufacturing, preclinical studies and human clinical trials, enabling Island to progress promising candidates more efficiently into advanced stages of development while maintaining a strong scientific and regulatory foundation.
This approach leverages prior investment in manufacturing, preclinical studies and human clinical trials, enabling Island to progress promising candidates more efficiently into advanced stages of development while maintaining a strong scientific and regulatory foundation.
ISLA-101: Advancing a Repurposed Antiviral
Island’s lead program, ISLA-101, exemplifies the benefits of a drug repurposing approach. Originally developed for other indications, ISLA-101 has an established safety and clinical data profile that enables Island to progress directly into targeted antiviral development.
This positions the program to address diseases such as dengue more efficiently, while leveraging prior work to support clinical trial design and regulatory engagement.
This positions the program to address diseases such as dengue more efficiently, while leveraging prior work to support clinical trial design and regulatory engagement.
Galidesivir: Broad-Spectrum Potential
Galidesivir further demonstrates the strength of Island’s strategy, having already undergone extensive preclinical and clinical evaluation, supported by significant historical investment and government funding.
As a broad-spectrum antiviral with activity across multiple RNA viruses, Galidesivir offers the potential to be developed across several high-impact indications, including emerging and high-consequence infectious diseases.
As a broad-spectrum antiviral with activity across multiple RNA viruses, Galidesivir offers the potential to be developed across several high-impact indications, including emerging and high-consequence infectious diseases.
Unlocking Value Through Existing Assets
Together, ISLA-101 and Galidesivir highlight how drug repurposing can unlock new therapeutic opportunities from existing assets.
By building on established data and focusing on well-understood biological targets, Island is able to advance its pipeline with greater speed and capital efficiency, while maintaining a strong scientific and regulatory foundation.
By building on established data and focusing on well-understood biological targets, Island is able to advance its pipeline with greater speed and capital efficiency, while maintaining a strong scientific and regulatory foundation.